|
1.
|
Bruix J and Sherman M; Practice Guidelines
Committee; American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
|
2.
|
Villanueva A, Newell P, Chiang DY,
Friedman SL and Llovet JM: Genomics and signaling pathways in
hepatocellular carcinoma. Semin Liver Dis. 27:55–76. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Llovet JM and Bruix J: Novel advancements
in the management of hepatocellular carcinoma in 2008. J Hepatol.
48(Suppl 1): S20–S37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Niu G, Wright KL, Huang M, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Real PJ, Sierra A, De Juan A, Segovia JC,
Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via
Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer
cells. Oncogene. 21:7611–7618. 2002. View Article : Google Scholar
|
|
6.
|
Wang T, Niu G, Kortylewski M, et al:
Regulation of the innate and adaptive immune responses by Stat-3
signaling in tumor cells. Nat Med. 10:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Schindler C, Levy DE and Decker T:
JAK-STAT signaling: from interferons to cytokines. J Biol Chem.
282:20059–20063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Alvarez JV, Febbo PG, Ramaswamy S, Loda M,
Richardson A and Frank DA: Identification of a genetic signature of
activated signal transducer and activator of transcription 3 in
human tumors. Cancer Res. 65:5054–5062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Bollrath J, Phesse TJ, von Burstin VA, et
al: gp130-mediated Stat3 activation in enterocytes regulates cell
survival and cell-cycle progression during colitis-associated
tumorigenesis. Cancer Cell. 15:91–102. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Garcia R, Bowman TL, Niu G, et al:
Constitutive activation of Stat3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast carcinoma
cells. Oncogene. 20:2499–2513. 2001. View Article : Google Scholar
|
|
11.
|
Liu Y, Liu A, Li H, Li C and Lin J:
Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced
JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Cancer Prev Res (Phila). 4:1296–1305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Yang J, Cai X, Lu W, et al: Evodiamine
inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in
hepatocellular carcinoma cells. Cancer Lett. 328:243–251. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Gu FM, Li QL, Gao Q, et al: Sorafenib
inhibits growth and metastasis of hepatocellular carcinoma by
blocking STAT3. World J Gastroenterol. 17:3922–3932. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Rajendran P, Ong TH, Chen L, et al:
Suppression of signal transducer and activator of transcription 3
activation by butein inhibits growth of human hepatocellular
carcinoma in vivo. Clin Cancer Res. 17:1425–1439. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Calvisi DF, Ladu S, Gorden A, et al:
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Gastroenterology. 130:1117–1128. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hu LF, Wong PT, Moore PK and Bian JS:
Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation
by inhibition of p38 mitogen-activated protein kinase in microglia.
J Neurochem. 100:1121–1128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Rose P, Moore PK, Ming SH, Nam OC,
Armstrong JS and Whiteman M: Hydrogen sulfide protects colon cancer
cells from chemopreventative agent beta-phenylethyl isothiocyanate
induced apoptosis. World J Gastroenterol. 11:3990–3997.
2005.PubMed/NCBI
|
|
18.
|
Lee ZW, Zhou J, Chen CS, et al: The
slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel
anti-cancer effects in vitro and in vivo. PLoS One. 6:e210772011.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Li L, Fox B, Keeble J, et al: The complex
effects of the slow-releasing hydrogen sulfide donor GYY4137 in a
model of acute joint inflammation and in human cartilage cells. J
Cell Mol Med. 17:365–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Takada Y, Ichikawa H, Badmaev V and
Aggarwal BB: Acetyl-11-keto-beta-boswellic acid potentiates
apoptosis, inhibits invasion, and abolishes osteoclastogenesis by
suppressing NF-kappa B and NF-kappa B-regulated gene expression. J
Immunol. 176:3127–3140. 2006. View Article : Google Scholar
|
|
21.
|
Isomoto H, Mott JL, Kobayashi S, et al:
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to
SOCS-3 epigenetic silencing. Gastroenterology. 132:384–396. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Won C, Lee CS, Lee JK, et al: CADPE
suppresses cyclin D1 expression in hepatocellular carcinoma by
blocking IL-6-induced STAT3 activation. Anticancer Res. 30:481–488.
2010.PubMed/NCBI
|
|
23.
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, et al: Signal transducer and activator of transcription-3,
inflammation, and cancer: how intimate is the relationship? Ann NY
Acad Sci. 1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Lufei C, Koh TH, Uchida T and Cao X: Pin1
is required for the Ser727 phosphorylation-dependent Stat3
activity. Oncogene. 26:7656–7664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Aziz MH, Manoharan HT, Church DR, et al:
Protein kinase Cepsilon interacts with signal transducers and
activators of transcription 3 (Stat3), phosphorylates Stat3Ser727,
and regulates its constitutive activation in prostate cancer.
Cancer Res. 67:8828–8838. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Selvendiran K, Kuppusamy ML, Ahmed S, et
al: Oxygenation inhibits ovarian tumor growth by downregulating
STAT3 and cyclin-D1 expressions. Cancer Biol Ther. 10:386–390.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Ai T, Wang Z, Zhang M, et al: Expression
and prognostic relevance of STAT3 and cyclin D1 in non-small cell
lung cancer. Int J Biol Markers. 27:e132–e138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Zhang K, Pang B, Xin T, et al: Increased
signal transducer and activator of transcription 3 (STAT3) and
decreased cyclin D1 in recurrent astrocytic tumours compared with
paired primary astrocytic tumours. J Int Med Res. 39:2103–2109.
2011. View Article : Google Scholar
|
|
29.
|
Sieghart W, Losert D, Strommer S, et al:
Mcl-1 overexpression in hepatocellular carcinoma: a potential
target for antisense therapy. J Hepatol. 44:151–157. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Bossy-Wetzel E and Green DR: Apoptosis:
checkpoint at the mitochondrial frontier. Mutat Res. 434:243–251.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Estaquier J, Vallette F, Vayssiere JL and
Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med
Biol. 942:157–183. 2012. View Article : Google Scholar
|
|
32.
|
Wurstle ML, Laussmann MA and Rehm M: The
central role of initiator caspase-9 in apoptosis signal
transduction and the regulation of its activation and activity on
the apoptosome. Exp Cell Res. 318:1213–1220. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Wei D, Le X, Zheng L, et al: Stat3
activation regulates the expression of vascular endothelial growth
factor and human pancreatic cancer angiogenesis and metastasis.
Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Zhu H, Feng Y, Zhang J, et al: Inhibition
of hypoxia inducible factor 1alpha expression suppresses the
progression of esophageal squamous cell carcinoma. Cancer Biol
Ther. 11:981–987. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Matsuyama T, Nakanishi K, Hayashi T, et
al: Expression of hypoxia-inducible factor-1alpha in esophageal
squamous cell carcinoma. Cancer Sci. 96:176–182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Yasuda S, Arii S, Mori A, et al:
Hexokinase II and VEGF expression in liver tumors: correlation with
hypoxia-inducible factor 1 alpha and its significance. J Hepatol.
40:117–123. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Tanaka H, Yamamoto M, Hashimoto N, et al:
Hypoxia-independent overexpression of hypoxia-inducible factor
1alpha as an early change in mouse hepatocarcinogenesis. Cancer
Res. 66:11263–11270. 2006. View Article : Google Scholar
|
|
38.
|
Moser C, Lang SA, Mori A, et al:
ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and
STAT3 activity in human hepatocellular carcinoma (HCC) cells, and
inhibits growth and vascularization in vivo. BMC Cancer. 8:2062008.
View Article : Google Scholar : PubMed/NCBI
|
